Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 2/20 | 0.56 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.36 |
| ▸ | RXRA | P19793 | 4/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721476 | 0.88 | STIM1 (0.47) | STIM1ORAI1SCN9ARXRANR1H2 | |
| SCHEMBL721713 | 0.86 | STIM1 (0.41) | STIM1ORAI1RXRANR1H2NR1H3 | |
| SCHEMBL14163289 | 0.78 | STIM1 (0.44) | STIM1ORAI1SCN9APTGS1PTGS2 | |
| SCHEMBL721462 | 0.73 | STIM1 (0.39) | STIM1ORAI1SCN9ARXRANR1H2 | |
| SCHEMBL10201041 | 0.72 | STIM1 (1.00) | STIM1ORAI1 | |
| SCHEMBL721295 | 0.71 | STIM1 (0.45) | STIM1ORAI1SCN9APTGS1PTGS2 | |
| SCHEMBL720446 | 0.68 | STIM1 (0.42) | STIM1ORAI1PTGS1PTGS2TNFRSF1A | |
| SCHEMBL724417 | 0.68 | STIM1 (0.44) | STIM1ORAI1 | |
| SCHEMBL14158727 | 0.68 | STIM1 (0.48) | STIM1ORAI1SCN9APTGS1PTGS2 | |
| SCHEMBL29642094 | 0.67 | KDR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336738-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-03 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2609095-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2012027710-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336738-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885SCN9A 235/4885 |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885SCN9A 235/4885 |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885SCN9A 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.